Evaluation of an irreversible, mutant-selective inhibitor of EGFR mutations
CO-1686 has demonstrated a good tolerability and promising efficacy against T790M epidermal growth factor receptor (EGFR) mutant non-small-cell lung cancer (NSCLC).
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.